Brought to you by 
Series B round garners $40mm for Anokion concurrent with Kanyos acquisition
13 Sep 2019
Executive Summary
Anokion SA (autoimmune disease drug development) raised $40mm through its Series B round from investors including Versant Ventures, Novartis Venture Fund, Novo Ventures, Celgene, and undisclosed Swiss private investors. Anokion also announced the acquisition of Kanyos Bio, a firm it spun out in 2015 to develop celiac disease and diabetes candidates. Series B proceeds will support development of Anokion's preclinical pipeline which includes its own ANK780 for multiple sclerosis, and KAN101, which it gains from Kanyos and will continuing developing for celiac disease.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B round garners $40mm for Anokion concurrent with Kanyos acquisition
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice